secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2022-01-14T23:59:59+00:00
Accession:  0001564590-22-001365
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics receives Nasdaq bid price deficiency notice; has until July 11, 2022 to regain compliance
--------------------------------------------------------------------------------

- Received deficiency letter from Nasdaq on Jan 10, 2022; bid price closed below $1.00 for 30 consecutive business days.
- Company has 180 calendar days (until July 11, 2022) to regain compliance by closing at $1.00+ for 10 consecutive days.
- If not compliant, may transfer to Nasdaq Capital Market for an additional 180-day compliance period, subject to other standards.
- May consider a reverse stock split or other measures to cure; no assurance of regaining compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022001365/0001564590-22-001365-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000156459022001365/trvi-8k_20220110.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-001365

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer